Search
Agkistrodon piscivorus antivenin
go.drugbank.com/drugs/DB13894ApprovedApproximately 99% of all venomous snake bites in the United States are caused by Crotalidae, also known as _pit vipers_. … The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalIt is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate
Tannic acid
go.drugbank.com/drugs/DB09372ApprovedInvestigationalTannic acid is also taken by mouth and applied directly for bleeding, chronic diarrhea, dysentery, bloody urine, painful joints, persistent coughs, and cancer. … Tannic acid is found in the nutgalls formed by insects on twigs of certain oak trees (Quercus infectoria and other Quercus species). It is removed and used as medicine.
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnIt has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Vestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalVestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with
APL-9
go.drugbank.com/drugs/DB16460InvestigationalIt shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.
Hydrogenated soybean oil
go.drugbank.com/drugs/DB11302ApprovedLinolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid.
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalIt is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections